HRP20240034T1 - Liječenje kardiovaskularnih bolesti - Google Patents
Liječenje kardiovaskularnih bolesti Download PDFInfo
- Publication number
- HRP20240034T1 HRP20240034T1 HRP20240034TT HRP20240034T HRP20240034T1 HR P20240034 T1 HRP20240034 T1 HR P20240034T1 HR P20240034T T HRP20240034T T HR P20240034TT HR P20240034 T HRP20240034 T HR P20240034T HR P20240034 T1 HRP20240034 T1 HR P20240034T1
- Authority
- HR
- Croatia
- Prior art keywords
- medicine
- use according
- pharmaceutically acceptable
- acceptable salts
- dose
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims 20
- 229940079593 drug Drugs 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 6
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 3
- 102400001263 NT-proBNP Human genes 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 3
- 229960004699 valsartan Drugs 0.000 claims 3
- 108010061435 Enalapril Proteins 0.000 claims 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
- 229960000873 enalapril Drugs 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- DOBNVUFHFMVMDB-BEFAXECRSA-N (2r,4s)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid Chemical compound C1=CC(C[C@H](C[C@@H](C)C(O)=O)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 DOBNVUFHFMVMDB-BEFAXECRSA-N 0.000 claims 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims 1
- 229960003953 sacubitril Drugs 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Claims (12)
1. Lijek, naznačen time, što sadrži
a) terapeutski učinkovitu količinu spoja formule
[(A1)(A2)](Na)y • x H2O (I)
gdje:
A1 je S-N-valeril-N-{[2'-(1H-tetrazol-5-il)-bifenil-4-il]-metil}-valin u njegovom anionskom obliku;
A2 je etil ester (2R,4S)-5-bifenil-4-il-4-(3-karboksi-propionilamino)-2-metil-pentanske kiseline u njegovom anionskom obliku;
Na je natrijev ion;
y je 3; i
x je 0 do 3;
ili
b) kombinaciju koja sadrži terapeutski učinkovitu količinu u molarnom omjeru 1:1
(i) valsartana ili njegove farmaceutski prihvatljive soli; i
(ii) sakubitrila ili njegove farmaceutski prihvatljive soli,
za uporabu u sprečavanju ili odgađanju vremena do prve pojave kardiovaskularne smrti kod ljudskog pacijenta koji pati od kroničnog sistoličkog zatajenja srca sa smanjenom ejekcijskom frakcijom.
2. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što pacijent prima osnovni tretman sa stabilnom dozom beta-blokatora.
3. Lijek za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, što lijek sadrži spoj formule (I) koji je trinatrijev [3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)propionat-(S)-3'-metil-2'-(pentanoil{2"-(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat]hemipentahidrat (LCZ696).
4. Lijek za uporabu prema patentnom zahtjevu 3, naznačen time, što se lijek daje oralno u dnevnoj dozi koja može doseći 400 mg, uzetoj u jednom ili više odvojenih uzimanja.
5. Lijek za uporabu prema patentnom zahtjevu 4, naznačen time, što se lijek daje oralno u dnevnoj dozi koja može doseći 400 mg, uzetoj u dva odvojena uzimanja (b.i.d.).
6. Lijek za uporabu prema patentnom zahtjevu 4 ili 5, naznačen time, što se lijek daje oralno u početnoj dozi od 100 mg b.i.d. u trajanju od jednog do dva tjedna i nakon toga titriranjem do 200 mg b.i.d.
7. Lijek za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, što lijek sadrži kombinaciju koja sadrži terapeutski učinkovitu količinu u molarnom omjeru 1:1
(i) valsartana ili njegove farmaceutski prihvatljive soli; i
(ii) sakubitrila ili njegove farmaceutski prihvatljive soli.
8. Lijek za uporabu prema patentnom zahtjevu 7, naznačen time, što se kombinacija treba davati oralno u dva odvojena uzimanja (b.i.d.) po danu, pri čemu svaki unos sadrži 103 mg valsartana, ili njegove farmaceutski prihvatljive soli, i 97 mg sakubitrila, ili njegove farmaceutski prihvatljive soli, po jedinici za doziranje.
9. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, što pacijent ima najmanje jednu od sljedećih dodatnih karakteristika
i) zatajenje srca prema NYHA razredu II, III ili IV,
ii) povišenu razinu BNP ili NT-proBNP u plazmi, poželjno BNP u plazmi ≥100 pg/mL (ili NT-proBNP ≥400 pg/mL), još poželjnije BNP u plazmi ≥150 pg/mL ili NT-proBNP ≥600 pg/mL, i
ii) smanjenu ejekcijsku frakciju lijeve klijetke (LVEF) od ≤40%.
10. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što pacijent ima smanjenu ejekcijsku frakciju lijeve klijetke (LVEF) od ≤35%.
11. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što je lijek učinkovitiji u sprečavanju ili odgađanju vremena do prve pojave kardiovaskularne smrti kod pacijenata koji pate od kroničnog sistoličkog zatajenja srca sa smanjenom ejekcijskom frakcijom, u usporedbi s enalaprilom primijenjenim dva puta dnevno u dozi od 10 mg.
12. Lijek za uporabu prema patentnom zahtjevu 11, naznačen time, što je lijek najmanje 15% učinkovitiji u sprečavanju ili odgađanju vremena do prve pojave kardiovaskularne smrti od lijeka koji sadrži enalapril primijenjenim dva puta dnevno u dozi od 10 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/056680 WO2015030711A1 (en) | 2013-08-26 | 2013-08-26 | New use |
| US201461972933P | 2014-03-31 | 2014-03-31 | |
| EP19202854.6A EP3626270B1 (en) | 2013-08-26 | 2014-08-26 | Treatment of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240034T1 true HRP20240034T1 (hr) | 2024-03-29 |
Family
ID=51494327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240034TT HRP20240034T1 (hr) | 2013-08-26 | 2014-08-26 | Liječenje kardiovaskularnih bolesti |
| HRP20200060TT HRP20200060T1 (hr) | 2013-08-26 | 2020-01-16 | Nova uporaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200060TT HRP20200060T1 (hr) | 2013-08-26 | 2020-01-16 | Nova uporaba |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160213646A1 (hr) |
| EP (3) | EP3626270B1 (hr) |
| JP (1) | JP6097888B2 (hr) |
| CY (1) | CY1122531T1 (hr) |
| DK (2) | DK3038654T3 (hr) |
| ES (1) | ES2767084T3 (hr) |
| FI (1) | FI3626270T3 (hr) |
| HR (2) | HRP20240034T1 (hr) |
| HU (2) | HUE064634T2 (hr) |
| LT (2) | LT3626270T (hr) |
| PL (2) | PL3626270T3 (hr) |
| PT (2) | PT3038654T (hr) |
| RS (2) | RS59816B1 (hr) |
| SI (2) | SI3626270T1 (hr) |
| WO (1) | WO2015028941A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562866B2 (en) * | 2015-02-06 | 2020-02-18 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
| EP3302460A1 (en) * | 2015-05-29 | 2018-04-11 | Novartis AG | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| CN107510653A (zh) * | 2016-06-17 | 2017-12-26 | 常州爱诺新睿医药技术有限公司 | 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法 |
| WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| CN106491600A (zh) * | 2015-09-06 | 2017-03-15 | 常州方楠医药技术有限公司 | 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| WO2017042700A1 (en) * | 2015-09-07 | 2017-03-16 | Sun Pharmaceutical Industries Limited | Solid forms of valsartan and sacubitril |
| CN106580908A (zh) * | 2015-10-16 | 2017-04-26 | 深圳信立泰药业股份有限公司 | 一种用于心血管疾病治疗的口服制剂及其制备方法 |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| CN108601741B (zh) * | 2016-02-03 | 2022-05-24 | 诺华股份有限公司 | 有机化合物的盖伦制剂 |
| CN106176681A (zh) * | 2016-08-25 | 2016-12-07 | 泰力特医药（湖北）有限公司 | 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法 |
| WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| US20210177803A1 (en) | 2018-08-23 | 2021-06-17 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| CA3151788A1 (en) * | 2019-09-20 | 2021-03-25 | Jingchao Sun | Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30484A (en) | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| ATE243515T1 (de) * | 1997-01-10 | 2003-07-15 | Merck & Co Inc | Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen |
| RU2334513C3 (ru) | 2002-01-17 | 2017-10-24 | Новартис Аг | Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep) |
| CA2525665A1 (en) * | 2003-05-16 | 2004-11-25 | Novartis Ag | Pharmaceutical composition comprising valsartan |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| FI3067043T3 (fi) | 2007-11-06 | 2023-03-18 | Novartis Ag | Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia |
| JP6041489B2 (ja) | 2008-11-22 | 2016-12-07 | ジェネンテック， インコーポレイテッド | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| ES2702529T3 (es) * | 2010-08-24 | 2019-03-01 | Novartis Ag | Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante |
| CA2882771C (en) | 2012-08-24 | 2021-02-23 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| US20160206597A1 (en) * | 2013-08-26 | 2016-07-21 | Toni Lynne Bransford | New Use |
-
2014
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en active Application Filing
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 EP EP23202190.7A patent/EP4321157A3/en active Pending
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en active Active
-
2020
- 2020-01-16 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI3626270T3 (fi) | 2024-01-11 |
| JP2016528303A (ja) | 2016-09-15 |
| LT3626270T (lt) | 2024-01-25 |
| US20160213646A1 (en) | 2016-07-28 |
| PT3626270T (pt) | 2024-01-11 |
| HRP20200060T1 (hr) | 2020-04-03 |
| DK3626270T3 (da) | 2024-01-15 |
| DK3038654T3 (da) | 2020-02-03 |
| EP3038654B1 (en) | 2019-10-30 |
| RS65037B1 (sr) | 2024-02-29 |
| CY1122531T1 (el) | 2021-01-27 |
| RS59816B1 (sr) | 2020-02-28 |
| ES2767084T3 (es) | 2020-06-16 |
| HUE047186T2 (hu) | 2020-04-28 |
| SI3038654T1 (sl) | 2020-02-28 |
| EP3626270A1 (en) | 2020-03-25 |
| US20210077461A1 (en) | 2021-03-18 |
| WO2015028941A1 (en) | 2015-03-05 |
| HUE064634T2 (hu) | 2024-04-28 |
| PL3626270T3 (pl) | 2024-04-08 |
| JP6097888B2 (ja) | 2017-03-15 |
| EP3038654A1 (en) | 2016-07-06 |
| LT3038654T (lt) | 2020-01-27 |
| EP3626270B1 (en) | 2023-10-11 |
| EP4321157A2 (en) | 2024-02-14 |
| EP4321157A3 (en) | 2024-05-15 |
| PT3038654T (pt) | 2020-02-04 |
| PL3038654T3 (pl) | 2020-05-18 |
| SI3626270T1 (sl) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
| JP2015519404A5 (hr) | ||
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| JP2015503593A5 (hr) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| HRP20230480T1 (hr) | Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca | |
| TW200838545A (en) | Therapeutic agent for painful disease | |
| JP2015526458A5 (hr) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| JP2012180381A5 (hr) | ||
| EP1849462A3 (en) | A method of alleviating signs and symptons of Spasticity | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2014180239A1 (zh) | 一种治疗重症高原病的药物组合物 | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| CN108619138B (zh) | 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途 | |
| JP2012041314A5 (hr) | ||
| JP2017508455A5 (hr) | ||
| EP2801373B1 (en) | Local administration-type pharmaceutical for improving dysphagia | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| JP2017513866A5 (hr) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| ATE546133T1 (de) | Orale dosierform mit trisubstituierten glycerin- verbindungen |